vTv Therapeutics Inc. (NASDAQ:VTVT) is up 8% in a week, although the company has not released any news recently. At the beginning of the month, the company released its Q2 2021 financial results and offered a corporate update on its clinical programs. CEO Steve Holcombe said that the company held a productive meeting with the FDA during the quarter after the grant of Breakthrough Therapy designation for TTP399 as a possible Type 1 diabetes adjunct treatment.
Holcombe said that based on the meeting, the company plans to carry two important TTP399 studies in 1H 2022. In addition, he said they look forward to continuing to engage the FDA to refine the studies in weeks to come.
Equally, vTv completed dosing of subjects in the first phase multiple ascending dose trial assessing tolerability, pharmacokinetics, and safety profile of its oral PDE4 inhibitor, HPP737. The company plans to evaluate HPP737 in psoriasis patients, and it is engaging the FDA in Q3 to discuss the study design with the trial expected to commence in Q4. With these clinical developments, investors should keep an eye on VTVT.
On Monday, VTVT stock moved up 2.16% at $1.89 with more than 325k shares, compared to its average volume of 1.31 million shares. The stock has moved within a range of $1.8401 – 1.9000 after opening the trade at $1.87.